A major pharmaceutical acquisition has just become a reality. Novo Nordisk, best known for developing Ozempic — one of the most popular treatments for obesity — has finalized a deal to acquire Akero Therapeutics for a staggering $5.2 billion.
What makes Akero Therapeutics such a valuable target? Primarily, its flagship drug candidate, efruxifermin (EFX). This compound is an analog of the human hormone FGF21, which plays a crucial role in regulating the body’s metabolism of fats and sugars. EFX reduces liver fat, suppresses inflammation, and can even reverse liver fibrosis — something that until recently was considered impossible.
EFX is seen as a key tool in the fight against MASH (Metabolic Dysfunction-Associated Steatohepatitis) — a chronic liver disease and an advanced form of fatty liver in which accumulated fat causes inflammation and cell damage. Over time, this can lead to fibrosis, cirrhosis, or even liver cancer.
The acquisition seems like a natural and strategic move. Novo Nordisk is already the global leader in treating obesity and diabetes, thanks to drugs such as Ozempic and Wegovy. MASH is one of the most serious complications associated with these metabolic conditions. By acquiring Akero, Novo Nordisk can now offer patients a more comprehensive treatment pathway — from prevention to advanced therapy.
However, it’s worth noting that $5.2 billion is an enormous price for a company whose flagship drug is not yet approved. Novo Nordisk is essentially paying for efruxifermin, which is not yet approved by the FDA; it is an experimental drug currently undergoing Phase 3 clinical trials. Despite promising early results, the final phase of clinical testing always carries a significant risk of failure.
Novo Nordisk insists that the acquisition will not impact its core financial budget, though the company admits it will likely lead to higher related expenses such as research and development. If everything goes according to plan, however, the Danish firm could soon add another “miracle drug” to its portfolio.